OrbiMed, Qiming lead $131m pre-IPO financing for late-stage clinical biopharma Minghui

OrbiMed, Qiming lead $131m pre-IPO financing for late-stage clinical biopharma Minghui

Photo by Raimond Klavins on Unsplash

Eudora Wang

10 August, 2025

Edited by: Padma Priya

autoimmune diseasesbiopharmaceuticalsclinical trialsMinghui PharmaceuticalOncologyOrbiMedQiming Venture Partners

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

You may also like

Read more from Greater China

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.